secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001193125-26-099376
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB-142 Phase 1 data shows C-peptide preservation in established T1D patients at Day 120
--------------------------------------------------------------------------------

- T1D cohort (n=6): 4 treated with SAB-142 (2.5 mg/kg) showed no decline in C-peptide at Day 120; mean values increased above baseline.
- Placebo participant (n=1) showed C-peptide decline consistent with predicted disease progression.
- Biomarker evidence of T cell exhaustion supports mechanism of action, per KOL Michael Haller, MD.
- SAFEGUARD Phase 2b trial enrolling new-onset Stage 3 T1D patients; topline data expected 2H 2027.
- Phase 1 previously met safety/PD objectives, enabling advancement to registrational trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526099376/0001193125-26-099376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526099376/sabs-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-099376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer